HBOT Conversations:
Dr. Peter Canaday (Part 2)
Dr. Peter Canaday has published work in Applied Physiology, Respiratory Medicine, and Diagnostic Radiology. He has presented at National (USA) and International meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on National, State, and Local advisory committees, and given testimony at the State Legislative level in the USA.
Dr. Canaday’s experience with Hyperbaric Oxygen Therapy dates back to the 1980s when he studied HBOT under Dr. Eric Kindwall, “The Father of Hyperbaric Medicine”. Dr. Canaday also co-founded the Hyperbaric Medicine Department at St. Anthony Hospital in Lakewood, Colorado.
From 2007, Dr. Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at a Midlands region DHB and served as Head of Department before retiring in March 2021.
Watch the Podcast
HBOT News Network welcomes Dr. Peter Canaday.
This is Part 2 of Conversations with Dr. Peter Canaday. Part 1 can be viewed here. Dr. Canaday now lives primarily in New Zealand, but his history with medicine and Hyperbaric Oxygen Therapy dates back over 40 years to the United States.
In this HBOT News Network Conversations, Dr. Canaday continues the discussion on COVID-19 vaccines and the suppression of medical data. di Girolamon asks the question, “where do we go from here?”. Dr. Canaday explains that Hyperbaric Oxygen Therapy is one of the most exciting things that has piqued his interest in the medical field. He explains that huge numbers are really starting to be revealed of people who have been negatively affected by COVID, either from the point of long-COVID or from a vaccine injury; and Hyperbaric Oxygen could be potentially very helpful to this population, as it is a natural therapy involving oxygen and pressure that upregulates the anti-inflammatory gene and down regulates the inflammatory gene.
However, Hyperbaric Oxygen Therapy threatens the pharmaceutical companies bottom line and when that happens we all start to see some pretty disturbing things start surfacing — such as the science being buried, fake studies being published showing HBOT to be ineffective, major medical Journals rejecting scientific articles outlining all the adverse affects from the vaccine.
The spirit of humanity needs to be embraced here, and it is not.
Dr. Canaday encourages viewers to learn more at www.nzdsos.com — it’s “New Zealand Doctors Speaking Out with Science“. The NZDSOS is very similar to America’s Frontline Doctors and there is a plethora of educational information that can be learned regarding what happened during the COVID-19 pandemic and is still happening today. Dr. Canaday further encourages us all to open our eyes, hearts and ears as we listen and digest to all of this information. Often times, it’s when doctors keep getting shut down and censored that we all need to be listening closer instead of turning the other cheek.
Dr. Canaday and di Girolamo stresses that everyone should be looking into the God-given miracle of Hyperbaric Oxygen Therapy. Be sure to find a treatment center near you if you are experiencing effects of long-COVID or a vaccine injury.
This HBOT News Conversation was filmed on October 4, 2022
Guest
Dr. Peter Canaday
Following completion of medical school at the University of Massachusetts in 1976, Dr. Peter Canaday took up training as an Internal Medicine specialist at the University of Michigan, followed by sub-specialist training in Respiratory and Intensive Care at the University of North Carolina. He began his medical career in a busy trauma hospital in Denver, Colorado in 1981 and practiced for 12 years. During his time there, he managed many of the types of patients now seen with severe COVID-19, co-founded a sleep disorders laboratory and a hyperbaric medicine department. As well, he participated in a dozen committee assignments, and rose to Chairman of the Department of Internal Medicine. In 1993, Dr Canaday changed career and completed training as a Radiologist at the University of Wisconsin in 1997. During an 8-year period at Creighton University Medical School in Nebraska, he became tenured as an Assistant Professor of Radiology, and head of the section of Pulmonary Radiology. He also served on or chaired over a dozen hospital and medical school committees and was appointed Clinical Coordinator for the Radiology Department during his time there. Dr Canaday has also published work in applied physiology, respiratory medicine, and diagnostic radiology, has presented at national (USA) and international meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on national, state, and local level advisory committees and given testimony at the state legislative level in the USA. From 2007, Dr Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at the Taranaki District Health Board and served as Head of Department before retiring in March 2021.
Subscribe Now, It’s Free!
Recent HBOT News
Toddler’s Brain Damage Reversed by Treatment After Near Drowning
USA Today Reports on the recovery of a 2-year-old Arkansas girl, Eden Carlson, who nearly drowned in her family's swimming pool. Her ordeal resulted in significant brain damage and her family was told that if she were to survive that she would not be able...
Effects of hyperbaric oxygen therapy on depression and anxiety in the patients with incomplete spinal cord injury (a STROBE-compliant article).
Little research has been done on the effects of hyperbaric oxygen (HBO) on depression and anxiety after spinal cord injury (SCI). The aim of this study was to investigate the effects of HBO on psychological problems and never function, especially on depression and anxiety in the patients with incomplete SCI (ISCI).Sixty patients with ISCI combined with depression and anxiety were randomly divided into HBO group (20 cases), psychotherapy group (20 cases), and conventional rehabilitation control group (20 cases). All patients received routine rehabilitation therapy. However, in HBO group and psychotherapy group, patients also received HBO and psychotherapy, respectively. These therapies lasted for a total of 8 weeks (once a day and 6 days per week). Before and after 8 weeks of treatment, depression and anxiety, nerve function, and activities of daily living were, respectively, evaluated according to Hamilton Depression (HAMD) scale, Hamilton Anxiety (HAMA) scale, American Spinal Injury Association score, and functional independence measure score in all patients.After 8 weeks of treatment, HAMD score was significantly lower in both HBO group and psychotherapy group than in control group (all P < .05), but there was no statistical difference in HAMD score between HBO group and psychotherapy group (P > .05). HAMA score was significantly lower in HBO group than in control group (P < .05), but there was no statistical difference in HAMA score between HBO group and psychotherapy group, and between psychotherapy group and control group (all P > .05). After 8 weeks of treatment, American Spinal Injury Association and functional independence measure scores were significantly higher in HBO group than in both psychological and control groups, and also higher in psychotherapy group than in control group (all P < .05).The effects of HBO on depression and anxiety are similar to that of psychotherapy. HBO can significantly improve nerve function and activities of daily living in the patients with ISCI, which either psychotherapy or routine rehabilitation therapy can not substitute.
Clinical Trial – The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness
The purpose of this study is to investigate the effect of spinal anesthesia on ED50 and BIS50
of etomidate for the loss of consciousness (LOC) by using up-and-down method.The hypothesis
was that spinal anesthesia could significantly reduce the etomidate bolus dose for the LOC
and could also achieve hemodynamic stability during anesthesia induction.